Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the treatment ...

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic referencing ...

If you want to know who really controls Hikma Pharmaceuticals PLC (LON:HIK), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the ...

Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, has deepened its collaboration with global biopharmaceutical leader Celltrion Inc through a series of exclusive licensing agreements ...

May 8 (Reuters) - Hikma Pharmaceuticals (HIK.L), opens new tab has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s ...

Hikma Pharmaceuticals USA has started work on a $1 billion investment that includes an expansion of its West Side facilities. The company, a division of London-based Hikma, officially broke ground ...

Xellia Pharmaceuticals is shedding its manufacturing operation in Bedford to a British manufacturer of pharmaceutical products. The Danish company that operates locally at the ex-Ben Venue ...